Study: Novo Nordisk NN9559-8577

Written By Patrick Smith

Are you living with type 2 diabetes and currently taking metformin alone, or metformin plus an SGLT-2 inhibitor (such as Jardiance, Farxiga, or Invokana)?

If so, you may be eligible to participate in a clinical research study assessing an investigational GLP-1 medicine called UBT251.

ABOUT THE STUDY

This is a Phase 2 study evaluating how UBT251 affects blood sugar, body weight, and heart health.

Who may qualify?

You may be eligible to participate if you meet all the following:

  • Age 18 to 75 years

  • Have type 2 diabetes

  • Currently taking metformin alone, or metformin plus an SGLT2 inhibitor (such as Jardiance, Farxiga, or Invokana)

  • HbA1c 7.0% to 10.5%

  • Body mass index (BMI) of 30 to 50 (classified as obesity)

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) within the past 3 months

  • Have not used Januvia, sulfonylureas (such as glyburide, glimepiride, or glipizide), or insulin within the past 3 months

  • Have never had surgery or a weight loss device for treatment of obesity

Interested in learning more?
Click below to complete a short questionnaire to see if you may be eligible.
(insert JotForm link)

Patrick Smith
Next

Study: Novo Nordisk NN9489-8033 “AMBITION 1”